Modulating active targeting nanoparticle design according to tumor progressions.

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Nanoparticle-based drug delivery systems show promise for cancer diagnosis and treatment.
• The influence of tumor progression on nanoparticle accumulation, particularly for active targeting nanoparticles, is not well understood.

Purpose of the Study:

• To investigate the accumulation and penetration of RGD-modified gold nanoparticles (active AuNPs) of varying sizes in orthotopic breast cancer models with different tumor progressions.
• To elucidate the relationship between nanoparticle size, tumor progression, and targeting efficiency.

Main Methods:

• Utilized RGD-modified gold nanoparticles (AuNPs) of different sizes.
• Investigated nanoparticle accumulation and penetration in orthotopic breast cancer models at various stages of progression.
• Analyzed the effects of tumor extracellular matrix properties and receptor expression on nanoparticle behavior.

Main Results:

• Smaller active AuNPs demonstrated superior accumulation and penetration in early-stage tumors, attributed to favorable tumor microenvironment characteristics (looser matrix, larger gaps, lower pressure).
• Larger active AuNPs showed enhanced accumulation and penetration in late-stage tumors, driven by multivalent interactions with highly expressed integrin αvβ3 receptors.
• Mid-stage tumors exhibited accumulation influenced by both size effects and multivalent interactions, with 7 nm and 90 nm active AuNPs showing significant accumulation.

Conclusions:

• Nanoparticle size plays a critical role in optimizing accumulation and penetration in tumors, with the optimal size dependent on tumor progression.
• Understanding the interplay between nanoparticle size, tumor microenvironment, and target receptor expression is crucial for designing effective targeted cancer therapies.
• This research provides guidance for the rational design of active targeting nanoparticles to improve cancer diagnosis and treatment outcomes based on tumor progression.